Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -10.67 USD | 5.07% |
| 2022 | -11.24 USD | 40.18% |
| 2021 | -18.79 USD | 34.37% |
| 2020 | -28.63 USD | -56.28% |
| 2019 | -18.32 USD | -119.89% |
| 2018 | 92.10 USD | 138.51% |
| 2017 | -239.13 USD | -123.36% |
| 2016 | -107.06 USD | 42.04% |
| 2015 | -184.70 USD | 18.89% |
| 2014 | -227.72 USD | -21.07% |
| 2013 | -188.09 USD | -83.79% |
| 2012 | -102.34 USD | 51.66% |
| 2011 | -211.73 USD | -53.94% |
| 2010 | -137.54 USD | -25850.94% |
| 2009 | -0.53 USD | -3.92% |
| 2008 | -0.51 USD | 1.92% |
| 2007 | -0.52 USD | -3109.88% |
| 2006 | -0.02 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 FY | - USD | 5.16% |
| 2023 Q2 | -1.82 USD | 62.63% |
| 2023 Q1 | -4.87 USD | -74.55% |
| 2023 Q3 | -1.53 USD | 15.93% |
| 2023 Q4 | -2.48 USD | -62.09% |
| 2022 Q3 | -8.51 USD | -205.02% |
| 2022 Q1 | -7.48 USD | -1491.49% |
| 2022 FY | - USD | 40.18% |
| 2022 Q4 | -2.79 USD | 67.22% |
| 2022 Q2 | -2.79 USD | 62.7% |
| 2021 Q4 | -0.47 USD | 91.3% |
| 2021 Q3 | -5.40 USD | 10.0% |
| 2021 Q1 | -6.00 USD | -1900.0% |
| 2021 Q2 | -6.00 USD | 0.0% |
| 2021 FY | - USD | 34.37% |
| 2020 Q2 | -6.00 USD | 33.33% |
| 2020 FY | - USD | -56.28% |
| 2020 Q1 | -9.00 USD | 0.0% |
| 2020 Q3 | -6.00 USD | 0.0% |
| 2020 Q4 | -0.30 USD | 95.0% |
| 2019 Q3 | -15.00 USD | -1463.64% |
| 2019 FY | - USD | -119.89% |
| 2019 Q4 | - USD | 100.0% |
| 2019 Q2 | 1.10 USD | 107.33% |
| 2019 Q1 | -15.00 USD | -1211.11% |
| 2018 Q3 | 18.00 USD | 20.0% |
| 2018 Q4 | 1.35 USD | -92.5% |
| 2018 FY | - USD | 138.51% |
| 2018 Q1 | 81.00 USD | 146.94% |
| 2018 Q2 | 15.00 USD | -81.48% |
| 2017 Q2 | -12.00 USD | -33.33% |
| 2017 FY | - USD | -123.36% |
| 2017 Q4 | -172.57 USD | -858.72% |
| 2017 Q3 | -18.00 USD | -50.0% |
| 2017 Q1 | -9.00 USD | 48.83% |
| 2016 FY | - USD | 42.04% |
| 2016 Q4 | -17.59 USD | 16.24% |
| 2016 Q2 | -30.00 USD | 23.08% |
| 2016 Q1 | -39.00 USD | -1.3% |
| 2016 Q3 | -21.00 USD | 30.0% |
| 2015 Q4 | -38.50 USD | 8.33% |
| 2015 Q2 | -42.00 USD | 0.0% |
| 2015 Q1 | -42.00 USD | 26.56% |
| 2015 Q3 | -42.00 USD | 0.0% |
| 2015 FY | - USD | 18.89% |
| 2014 Q2 | -51.00 USD | 26.09% |
| 2014 Q4 | -57.19 USD | -5.91% |
| 2014 Q3 | -54.00 USD | -5.88% |
| 2014 FY | - USD | -21.07% |
| 2014 Q1 | -69.00 USD | -31.3% |
| 2013 FY | - USD | -83.79% |
| 2013 Q2 | -51.00 USD | -54.55% |
| 2013 Q3 | -48.00 USD | 5.88% |
| 2013 Q4 | -52.55 USD | -9.48% |
| 2013 Q1 | -33.00 USD | -5.4% |
| 2012 Q4 | -31.31 USD | -49.1% |
| 2012 FY | - USD | 51.66% |
| 2012 Q3 | -21.00 USD | 12.5% |
| 2012 Q2 | -24.00 USD | 11.11% |
| 2012 Q1 | -27.00 USD | 38.57% |
| 2011 Q4 | -43.95 USD | -62.78% |
| 2011 Q1 | -147.00 USD | -188.69% |
| 2011 FY | - USD | -53.94% |
| 2011 Q3 | -27.00 USD | 10.0% |
| 2011 Q2 | -30.00 USD | 79.59% |
| 2010 Q1 | -33.00 USD | -246.64% |
| 2010 Q2 | -21.00 USD | 36.36% |
| 2010 Q3 | -42.00 USD | -100.0% |
| 2010 Q4 | -50.92 USD | -21.24% |
| 2010 FY | - USD | -25850.94% |
| 2009 FY | - USD | -3.92% |
| 2009 Q1 | -0.17 USD | 0.0% |
| 2009 Q4 | -9.52 USD | 20.67% |
| 2009 Q3 | -12.00 USD | 42.86% |
| 2009 Q2 | -21.00 USD | -12252.94% |
| 2008 Q2 | -0.05 USD | 82.17% |
| 2008 Q3 | -0.15 USD | -180.37% |
| 2008 Q4 | - USD | 100.0% |
| 2008 FY | - USD | 1.92% |
| 2008 Q1 | -0.30 USD | -100.0% |
| 2007 Q4 | -0.15 USD | 0.0% |
| 2007 Q1 | -0.00 USD | -20.0% |
| 2007 Q2 | -0.30 USD | -6150.0% |
| 2007 FY | - USD | -3109.88% |
| 2007 Q3 | -0.15 USD | 50.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | -0.00 USD | 0.0% |
| 2006 Q3 | -0.00 USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | -1678.333% |
| Armata Pharmaceuticals, Inc. | -1.91 USD | -458.639% |
| Actinium Pharmaceuticals, Inc. | -1.83 USD | -483.06% |
| Azitra, Inc. | -54.76 USD | 80.515% |
| Can-Fite BioPharma Ltd. | -1.79 USD | -496.089% |
| Chromocell Therapeutics Corporation | -1.28 USD | -733.594% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | -516.763% |
| CEL-SCI Corporation | -0.73 USD | -1361.644% |
| iBio, Inc. | -6.50 USD | -64.154% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | -8791.667% |
| MAIA Biotechnology, Inc. | -1.49 USD | -616.107% |
| Matinas BioPharma Holdings, Inc. | -5.28 USD | -102.083% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -1708.475% |
| NovaBay Pharmaceuticals, Inc. | -138.65 USD | 92.304% |
| NanoViricides, Inc. | -0.70 USD | -1424.286% |
| Oragenics, Inc. | -9.18 USD | -16.231% |
| BiomX Inc. | -5.10 USD | -109.216% |
| BiomX Inc. | -5.10 USD | -109.216% |
| Protalix BioTherapeutics, Inc. | 0.12 USD | 8991.667% |
| Palatin Technologies, Inc. | -2.02 USD | -428.218% |
| Scorpius Holdings, Inc. | -347.20 USD | 96.927% |